Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Dermatology

BMS’s Deucravacitinib Superior to Otezla (apremilast) and Placebo in POETYK PSO-2 Psoriasis Trial

Bristol-Myers Squibb announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib for the treatment of […]

BMS’s Deucravacitinib Superior to Otezla (apremilast) and Placebo in POETYK PSO-2 Psoriasis Trial
1 month ago
Share

Verrica Pharmaceuticals Presents Positive Results for Molluscum, Genital Warts Treatment

Verrica Pharmaceuticals presented data two clinical trials evaluating the safety and efficacy of VP-102, a proprietary drug-device combination product in […]

Verrica Pharmaceuticals Presents Positive Results for Molluscum, Genital Warts Treatment
2 months ago
Share

Oncosec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

Oncosec Medical announced positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO (tavokinogene telseplasmid) in combination […]

Oncosec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
4 months ago
Share

Arena Pharma’s Etrasimod Effective in Treating Atopic Dermatitis in Phase 2b Trial

Arena Pharmaceuticals announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod for the treatment of moderate-to-severe atopic […]

Arena Pharma’s Etrasimod Effective in Treating Atopic Dermatitis in Phase 2b Trial
4 months ago
Share

Bristol Myers Squibb’s Deucravacitinib Superior to Amgen’s Otezla (apremilast) and Placebo in Pivotal Phase 3 Psoriasis Study

Bristol-Myers Squibb reported positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165) versus Otezla (apremilast) […]

Bristol Myers Squibb’s Deucravacitinib Superior to Amgen’s Otezla (apremilast) and Placebo in Pivotal Phase 3 Psoriasis Study
4 months ago
Share

Biogen Reports Data for Systemic Lupus Erythematosus Portion of Phase 2 LILAC Study Showing Efficacy of BIIB059 in Reducing Joint Disease Activity

Biogen announced positive data from the 24-week systemic lupus erythematosus (SLE) portion of the Phase 2 LILAC study (part A) […]

Biogen Reports Data for Systemic Lupus Erythematosus Portion of Phase 2 LILAC Study Showing Efficacy of BIIB059 in Reducing Joint Disease Activity
4 months ago
Share

ChemoCentryx Announces Positive Topline Results from Phase 2 AURORA Trial of Avacopan for Hidradenitis Suppurativa

ChemoCentryx reported positive topline results from the phase 2 AURORA trial which evaluated the efficacy of avacopan versus placebo in […]

ChemoCentryx Announces Positive Topline Results from Phase 2 AURORA Trial of Avacopan for Hidradenitis Suppurativa
4 months ago
Share

Data from Soligenix Phase 3 FLASH Study Shows Continued Long-Term Benefit of SGX301 in Treating Cutaneous T-Cell Lymphoma

Soligenix announced results from the compassionate use, optional cycle (cycle 3) of the phase 3 FLASH trial, which evaluated SGX301 […]

Data from Soligenix Phase 3 FLASH Study Shows Continued Long-Term Benefit of SGX301 in Treating Cutaneous T-Cell Lymphoma
5 months ago
Share

LEO Pharma Announces Data from ECZTRA 1, 2 and ECZTRA 3 Phase 3 trials Published in British Journal of Dermatology

LEO Pharma announced that the British Journal of Dermatology has published primary data from the pivotal ECZTRA 1, 2 and ECZTRA 3 […]

LEO Pharma Announces Data from ECZTRA 1, 2 and ECZTRA 3 Phase 3 trials Published in British Journal of Dermatology
5 months ago
Share

Corbus’ Lenabasum Fails to Meet Endpoints in Phase 3 Systemic Sclerosis Trial

Corbus Pharmaceuticals announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic […]

Corbus' Lenabasum Fails to Meet Endpoints in Phase 3 Systemic Sclerosis Trial
6 months ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.